Clinical Trial Update: A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. [Phase 2]

View source ↗

Summary

Phase 2 trial exploring nab-paclitaxel with camrelizumab and famitinib in first-line triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib (Famitinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Fudan University | Conditions: Triple-Negative Breast Cancer | Phase 2 | Status: UNKNOWN